The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
SGLT2i: beyond the glucose-lowering effect
Open accessAbstract
Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, greatly improve the quality of life of patients, and reduce medical expenses for families and society. As adverse cardiac and renal events are the most common and serious complications of T2DM, it is very important to understand the cardio- and renoprotective mechanisms of SGLT2i. This article reviews the historical development, pharmacological mechanism, heart and kidney protection and safety of SGLT2i. The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Research works printed but not linked: 63
- Mugeni R, Aduwo JY, Briker SM, Hormenu T, Sumner AE, Horlyck-Romanovsky MF. A review of diabetes prediction Equations in African descent populations. Front Endocrinol. 2019;10:663. · DOI
- Fernandez-Twinn DS, Hjort L, Novakovic B, Ozanne SE, Saffery R. Intrauterine programming of obesity and type 2 diabetes. Diabetologia. 2019;62(10):1789–801. · DOI · Paper page
- Wei W, Ehlerding EB, Lan X, Luo QY, Cai W. Molecular imaging of beta-cells: diabetes and beyond. Adv Drug Deliv Rev. 2019;139:16–31. · DOI
- Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: A reappraisal. Diab Obes Metab. 2020;22(6):904–15. · DOI
- Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and the kidney: insights from cardiovascular outcome trials. Diab Obes Metab. 2019;21(8):1790–800. · DOI
- Gorgojo-Martinez JJ. New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus. Hipertension y Riesgo Vascular. 2019;36(3):145–61. · DOI
- Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: jACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422–34. · DOI · Paper page
- Rajasekeran H, Cherney DZ, Lovshin JA. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? Curr Opin Nephrol Hypertens. 2017;26(5):358–67. · DOI
- Nincevic V, OmanovicKolaric T, Roguljic H, Kizivat T, Smolic M, BilicCurcic I. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Molr Sci. 2019;20(23):5831. · DOI
- Chilton RJ. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diab Obes Metab. 2020;22(1):16–29. · DOI
- Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diab Metab Res Rev. 2005;21(1):31–8. · DOI · Paper page
- Jung CH, Jang JE, Park JY. A novel therapeutic agent for Type 2 diabetes mellitus: sGLT2 inhibitor. Diab Metab J. 2014;38(4):261–73. · DOI
- Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, Pontecorvi A, Giaccari A. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascu Diabetol. 2019;18(1):20. · DOI · Paper page
- Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med. 2013;34(2–3):183–96. · DOI · Paper page
- Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873–82. · DOI · Paper page
- Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, Rueff J. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int. 2006;69(5):852–5. · DOI
- Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008;23(12):3874–9. · DOI
- Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes. 2019;68(2):248–57. · DOI
- Pirklbauer M, Schupart R, Fuchs L, Staudinger P, Corazza U, Sallaberger S, Leierer J, Mayer G, Schramek H. Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. Am J Physiol Renal Physiol. 2019;316(3):F449–f462. · DOI
- Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, Matsuoka TA, Kaku K. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic beta-cell function and reduction of insulin resistance. J Diab. 2017;9(3):219–25. · DOI
- Sargent J. Therapy: SGLT2 inhibitor dapagliflozin promotes glucagon secretion in alpha islet cells. Nat Rev Endocrinol. 2015;11(7):382. · DOI
- Liu Z, Fu C, Wang W, Xu B. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients–a cross-sectional hospital based survey in urban China. Health Quality Life Outcomes. 2010;8:62. · DOI · Paper page
- Zhang HBXH, Yang YZ, et al. An analysis of the correlation between tumors and death caused of diabetic inpatients in 15 provinces from 1991 to 2005. Chin J Diabetes. 2009;17(1):6–8.
- Docherty KF, Jhund PS, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020. https://doi.org/10.1093/eurheartj/ehaa183. · DOI · Paper page
- Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovascu Diabetol. 2019;18(1):76. · DOI
- Bonora BM, de Kreutzenberg SV, Avogaro A, Fadini GP. Effects of the SGLT2 inhibitor dapagliflozin. Cardiovascu Diabetol. 2019;18(1):106. · DOI
- Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 Inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME Study. Diab Care. 2016;39(5):717–25. · DOI · Paper page
- Shrikrishnapalasuriyar N, Shaikh A, Ruslan AM, Sharaf G, Udiawar M, Price DE, Stephens JW. Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK. Diab Metab Syndrome. 2020;14(3):237–9. · DOI
- Gilbert RE, Connelly KA. Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovas Diabetol. 2019;18(1):6. · DOI
- Coleman RL, Gray AM, Broedl UC, Fitchett D, George JT, Woerle HJ, Zinman B, Holman RR. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels. Diab Obes Metab. 2020. https://doi.org/10.1111/dom.14017. · DOI
- Yaribeygi H, Lhaf F, Sathyapalan T, Sahebkar A. Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: implications for lowering tissue damage. Life Sci. 2019;231:116538. · DOI
- Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biol Med. 2017;104:298–310. · DOI · Paper page
- Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovascu Diabetol. 2019;18(1):15. · DOI · Paper page
- Sun HY, Wang NP, Halkos ME, Kerendi F, Kin H, Wang RX, Guyton RA, Zhao ZQ. Involvement of Na +/H + exchanger in hypoxia/re-oxygenation-induced neonatal rat cardiomyocyte apoptosis. Eur J Pharmacol. 2004;486(2):121–31. · doi:10.1016/j.ejphar.2003.12.016
- Cingolani HE, Rebolledo OR, Portiansky EL, Perez NG, de CamilionHurtado MC. Regression of hypertensive myocardial fibrosis by Na(+)/H(+) exchange inhibition. Hypertension. 2003;41(2):373–7 (Dallas, Tex : 1979). · doi:10.1161/01.hyp.0000051502.93374.1c
- Young M, Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology. 2003;144(9):3848–51. · DOI
- Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288(5):H2031–41. · DOI · Paper page
- Hussein AM, Eid EA, Taha M, Elshazli RM, Bedir RF, Lashin LS. Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in Type 2 diabetic rats: possible underlying mechanisms. Biomedicines. 2020;8(3):43. · DOI
- Yang Y, Zhao C, Ye Y, Yu M, Qu X. Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes. Front Endocrinol. 2020;11:190. · DOI
- Kario K, Ferdinand KC, O’Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progr Cardiovascu Dis. 2020. https://doi.org/10.1016/j.pcad.2020.04.003. · DOI
- Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL: Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. Journal of the American Heart Association 2017, 6(5). · DOI · Paper page
- Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011;170:1–7. · DOI · Paper page
- Yang G, Zhang M, Zhang M, Chen S, Chen P. Effect of Huangshukuihua (Flos Abelmoschi Manihot) on diabetic nephropathy: a meta-analysis. J Trad Chin Med = Chung i tsa chih ying wen pan. 2015;35(1):15–20.
- Chamberlain JJ, Doyle-Delgado K, Peterson L, Skolnik N. Diabetes Technology: review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2019;171(6):415–20. · DOI
- Association TMCGoCD. Chinese clinical practice guideline of diabetic kidney disease. Chin J Diab Mellitus. 2019;11(1):15–28.
- Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019;131(4):251–60. · DOI
- Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L. SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina. 2019;55(6):268. · DOI
- Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, et al. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovascu Diabetol. 2019;18(1):110. · DOI
- Fishman B, Shlomai G, Twig G, Derazne E, Tenenbaum A, Fisman EZ, Leiba A, Grossman E. Grossman E: Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents. Cardiovascu Diabetol. 2019;18(1):124. · DOI
- Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol. 2016;29(3):391–400. · DOI
- Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(12):2219–31. · DOI
- Ji LNGL, Guo XH, Hong TP, Huo Y, Ji QH, Kuang HY, Li H, Li Q, Li Y, Lam KS, Lu JM, Mu YM, Dan ZY, Tong NW, Wang WQ, Yang WY, Zhou ZG, Zhu DL, Zou DJ. Expert guidance on clinical practice of sodium glucose co-transporter 2 inhibitor in China. Chin J Diab. 2016;24(10):865–70.
- Wilding J. SGLT2 inhibitors and urinary tract infections. Nat Rev Endocrinol. 2019;15(12):687–8. · DOI
- Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diab Care. 2015;38(9):1687–93. · DOI · Paper page
- Levine JA, Karam SL, Aleppo G. SGLT2-I in the Hospital Setting: diabetic Ketoacidosis and other benefits and concerns. Curr Diab Rep. 2017;17(7):54. · DOI
- Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diab Metab Res Rev. 2017;33(5):e2886. · DOI · Paper page
- Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X. Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk. Front Pharmacol. 2018;9:1517. · DOI
- Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diab Care. 2018;41(1):e4–5. · DOI · Paper page
- Li D, Yang JY, Wang T, Shen S, Tang H. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diab Metab. 2018;44(5):410–4. · DOI
- De Jonghe S, Johnson MD, Mamidi R, Vinken P, Feyen B, Lammens G, Proctor J. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study. Chem Biol Interact. 2017;277:85–90. · DOI
- De Jonghe S, Proctor J, Vinken P, Feyen B, Wynant I, Marien D, Geys H, Mamidi RN, Johnson MD. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact. 2014;224:1–12. · DOI
- Fitchett D. A safety update on sodium glucose co-transporter 2 inhibitors. Diab Obes Metab. 2019;21(Suppl 2):34–42. · DOI · Paper page
- Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130(1):72–82. · DOI
Cited by
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users
Tallarico, R. T., Jing, B., Lu, K., Chawla, S. A., Luo, Y., Badathala, A., Chen, C. L., Wallace, A. W., & Legrand, M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.0940 · Cited by 40
Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., et al. (2023) · Antioxidants · doi:10.3390/antiox13010016 · Cited by 35
Girardi, A. C. C., Polidoro, J. Z., Castro, P. C., Pio-Abreu, A., Noronha, I. L., & Drager, L. F. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00143.2024 · Cited by 32
Metadata
- Authors
- Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X.
- Venue
- Cardiovascular Diabetology
- Published
- 2020-06-26
- Volume
- 19
- Issue
- 1
- Pages
- 98-98
- ISSN
- 1475-2840 (ISSN-L)
- OpenAlex
- W3038036007
- Cited by
- 230
- References
- 20
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SGLT2i: beyond the glucose-lowering effect. https://app.cochat.ai/papers/10.1186/s12933-020-01071-y
- The paper
- Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020). SGLT2i: beyond the glucose-lowering effect. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-020-01071-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.